More recently, in a randomized, double-blind, placebo-controlled trial of Ld-IL2 therapy in SLE, no serious infection was observed in the IL-2 group, in contrast to two cases in the placebo group, again supporting this notion [46,47]. This evidence concerns the gene IL2 and systemic lupus erythematosus.